A phase II study of 9-aminocamptothecin in patients with refractory breast cancer

Cancer Investigation

Volumn 18, Issue 1, 2000, Pages 28-31

  Kraut, Eric H ^a,f   Balcerzak, Stanley P ^a   Young, Donn ^a   O'Rourke, Mark A ^b   Petrus, John J ^c   Kuebler, J Philip ^d   Mayernik, David G ^e  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Cancer Centers of the Carolinas   (United States)

^c Akron General Hospital   (United States)

^d RIVERSIDE METHODIST HOSPITAL   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f Phase II Research Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRANULOCYTOPENIA; HUMAN; INFECTION; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; VOMITING;

EID: 0033953507     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009023059     Document Type: Article

References (12)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics 1998. CA Cancer J Clin 48:6-29, 1998.
2. Honig SF: Hormonal therapy and chemotherapy. In: Diseases of the Breast, edited by JR Harris, ME Lippman, M Morrow, S Hellman, Philadelphia, Lippincott-Raven, 1996, pp 669-734.
3. Burris HA, Fields SM: Topoisomerase I inhibitors. Hematol Oncol Clin North Am 8:333-355, 1994.
4. Wang JC: DNA topoisomerase. Annu Rev Biochem 65:635-692, 1996.
5. D'arpa P, Liu LF: Topoisomerase targeting antitumor drugs. Biochem Biophys Acta 989:163-167, 1989.
6. Tanizawa A, Fujimiori A, Pommier Y: Comparison of topoisomerase I inhibitors, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842, 1994.
7. Hsiang YH, Liu LF, Wall M, et al: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4835-4839, 1989.
8. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 54:1431-1439, 1994.
9. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10:1-10, 1989.
10. Crow MK, Soo E, Holmes FA: Metastatic Breast Cancer in Medical Oncology, Huntington, New York, PRR publication, 1995, pp 301-325.
11. Wenger CR, Beardslee S, Owens MA, et al: DNA ploidy, S-phase and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28:9-20, 1993.
12. Pommier Y, Leteurtre F, Fesen MR, et al: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12:530-542, 1994.